**Supplementary Figure 4.** SLC2A12 is an AR target. LAPC4 (A) or VCaP (B) cells were cotreated ± 10 μM enzalutamide (antiandrogen) with increasing concentrations of androgen (0, 100 pM or 10 nM R1881) for 72 h. SLC2A12 mRNA levels were quantified using qRT-PCR and normalized to 36B4 levels. *, significant (P<0.05) changes from vehicle (no androgen) treatment. #, significant (P<0.05) changes from vehicle (no enzalutamide) treatment.